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Abstract
The MST1R (RON) gene, that maps at 3p21.3, encodes a protein tyrosine kinase receptor comprised of an extra-cellular domain that
contains the ligand binding pocket and an intracellular region where the kinase domain is located. It controls cell survival and motility
programs related to invasive growth. With the single strand conformation polymorphism (SSCP) method, a C to A nucleotide polymorphism
(SNP) was found in intron 18 of the gene. The SNP has a frequency of 0.28 among African–American, 0.25 among Caucasian CEPH and
0.09 among Asian healthy individuals. During these studies, an alternatively spliced cDNA of MST1R, lacking exon 19, was also found that
may result from this change.
q 2003 Elsevier Science Ltd. All rights reserved.
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1. Introduction
The macrophage stimulating 1 receptor, MST1R (RON,
OMIM; 600168) gene maps at 3p21.3, a region critical for
breast and lung cancer [1]. MST1R protein signaling can be
abnormally activated through several mechanisms.
The experimental introduction of tumorigenic point
mutations found in MET and KIT activates the oncogenic
potential of RON [2]. The mouse and avian orthologs of
RON (stk and sea, respectively) are involved in oncogenesis
through the participation of viral component [3,4].
Rare splicing variants found in gastric carcinomas and
cell lines lead to aberrant dimerization and constitutive
activation of RON [5].
However, so far RON has been found to be involved in
naturally occurring human tumors through over-expression.
This is the case of breast and colon cancer. In normal breast
epithelium and benign lesions, the protein is expressed at
a very low level but the expression level increases
significantly in infiltrating carcinomas [6]. Similarly, colon
carcinoma cell lines show a high level of expression and
constitutive activation of RON whereas normal epithelial
colon cells do not [7,8]. Moreover, Ron was found highly
expressed also in a number of non-small cell lung cancer [9]
and activated in bronchioalveolar carcinomas (Danilkovitch
et al., personal communication).
Using the single strand conformation polymorphism
(SSCP) method we performed mutation analysis of several
breast, renal and lung cancer samples in which the RON
gene and the surrounding genomic region were found
amplified (Zabarowsky et al., manuscript in preparation).
During these studies a new single nucleotide polymorphism
(SNP) was found: a C to A transversion that occurs 10 bp
upstream of the acceptor splice site of intron 18 (GenBank
entry: AF164652). The SNP frequency was evaluated in
three different ethnic groups. An alternatively spliced cDNA
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lacking exon 19 was also found, along with the wild type
cDNA, in a lung cancer cell line with the polymorphism.
2. Materials and methods
2.1. Human DNA
Signed, informed consent was obtained from all
participants in the study, according to the NCI institutional
review board-approved protocol.
2.2. Cell lines
Lung cancer cell lines NCI-H358, NCI-H1650,
NCI-H1666 and NCI-H1781 were obtained from ATCC
(Manassas, VA).
2.3. PCR primers
Primers were synthesized by ABI Applied Biosystems
(Frederick, MD).
in 18 Fw: 50 TTC CAG CTG AAG GAC TCT GG
in 19 Rv: 50 ACT ACC ACC TCC ACA TAC TC
ex 18 Fw: 50 ATC CTG GAC AGG GAG TAC
ex5 Rv: 50 TCC CCA AGC AGT GCA GAC ACT ATC
TG
2.4. PCR–SSCP analysis
The radioactive labeling reaction was performed in a
total reaction volume of 12.5 ml, containing 100 ng of
genomic DNA, 12.5 pmol of each primer (in 18-Fw, in
19-Rv), 200 mM dNTPs, 1.5 mM MgCl2, 1.25 nCi
a35S-dATP. Primers amplified a single band (255 bp)
under the following cycling conditions: 3 min at 95 8C;
(30 s at 95 8C, 30 s at 60 8C, 30 s at 72 8C) for 35 cycles;
7 min extension at 72 8C. After heat denaturation (8 min at
90 8C) in formamide buffer (Stop Solution, Amersham,
Arlington Heights, IL), PCR products were run overnight in
a 0.5 £ MDE gel (FMC Bioproducts, Rockland, ME),
0.6 £ TBE, at room temperature, 8 W constant power;
transferred on 3 mm paper, dried and exposed to auto-
radiography film (X-OMAT AR, Kodak, Rochester, NY).
2.5. RT-PCR
First strand cDNAs were reverse transcribed from
random primed total RNA isolated from cell lines above
(cDNA Cycle Kit, Invitrogen, Carslbad, CA). MST1R
cDNA was amplified with the primers ex18-Fw, ex5-Rv
(PCR product: 356 bp) under the following conditions:
Table 1
Frequency of the SNP in three different ethnic groups
Ethnic group Genotype Frequency of allele A
CC CA AA
African–American 15 5 1 0.28
Asian 18 2 0 0.09
Caucasian (CEPH) 19 8 0 0.25
Fig. 1. SSCP analysis of the CEPH Family 1362 [10] shows Mendelian
inheritance of the C to A SNP located in intron 18 (GenBank entry:
AF164652) of the MST1R gene. (A) pedigree of Family 1362. (B) SSCP
profile of allele ‘C’ and allele ‘A’ and corresponding sequence of
subcloning products.
Fig. 2. Alternative splicing of exon 19 is present along with wildtype
splicing in the SNP-carrier cell line H1650. (A) SSCP analysis of gDNA.
(1) H1650 (‘AA’), (2) NCI-H358, (3) NCI-H1781, (4) NCI-H1666 (all
‘CC’). (B) Sequence of the alternatively spliced cDNA. The arrow points to
the splice junction between exons 18 and 20.
D. Angeloni et al. / Molecular and Cellular Probes 17 (2003) 55–5756
3 min at 95 8C; (30 s at 95 8C, 30 s at 62 8C, 30 s at 72 8C)
for 35 cycles; 7 min extension at 72 8C.
2.6. Sequencing
PCR products were cloned into the pCR2.1-TOPO vector
(TA Cloning Kit, Invitrogen, Carslbad, CA) and several
single colonies were isolated and sequenced.
Sequencing reactions were performed on an ABI 373
Stretch Automated DNA Sequencer (Applied Biosystems,
Foster City, CA).
3. Results and discussion
A C to A transversion was found 10 bp upstream the
acceptor splice site of the MST1R gene intron 18
(nucleotide 414 GenBank entry AF164652), it introduces
a new XcmI site at base 92 of the 255 bp PCR product
(Section 2). Three different ethnic groups were analyzed to
establish the frequency of allele A in the general healthy
population (Table 1). One carrier family (CEPH Family
1362 [10]) was analyzed to prove Mendelian inheritance of
the genotypic trait (Fig. 1).
To investigate a possible effect of the SNP on the splicing
process, we analyzed MST1R cDNA from cell lines
homozygous for the ‘A’ (NCI-H1650), ‘C’ (NCI-H358,
NCI-H1781 and NCI-H1666) alleles (Fig. 2A). Amplifica-
tion of NCI-H1650 cDNA with PCR primers designed
across exon 19 (ex18Fw, ex5Rv) yielded two bands (data not
shown): the expected 356 bp product with wildtype
sequence and a less abundant, alternatively spliced 219 bp
product, lacking exon 19 (Fig. 2B). Under the conditions
used the alternatively spliced cDNA was not amplified from
cell lines with the C allele.
Because this polymorphism affects exon 19, a part of the
MST1R kinase domain, we plan to test the hypothesis that it
may lead to a predisposition for cancer.
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